CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2014—Horizon Discovery entered into a nonexclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene-editing system.
Under the terms of the agreement, Horizon has rights to use the technology commercially for applications including development of research tools and reagents. The company also has rights to provide services that use CRISPR, such as Horizon’s Genassist offering. Genassist is a comprehensive product and service solution for CRISPR and rAAV gene editing, including guide RNA design and validation, donor design, and a wide range of off-the-shelf plasmids.
The Broad Institute patent represents the first granted patent for use of CRISPR technology in eukaryotic cells. Recently published results indicate that CRISPR/Cas9-mediated gene editing can be employed in high-throughput genomewide screens.
Horizon Discovery Group, 44 (0) 1223 655 580